keyword
MENU ▼
Read by QxMD icon Read
search

locally advanced lung cancer surgery

keyword
https://www.readbyqxmd.com/read/27914779/what-do-radiation-oncologists-require-for-future-advancements-in-lung-sbrt
#1
REVIEW
Umberto Ricardi, Serena Badellino, Andrea Riccardo Filippi
Stereotactic Body Radiotherapy (SBRT) is a well established therapeutic option for patients affected with peripheral early stage non-small cell lung cancer (NSCLC), given the positive clinical evidence accumulated so far on its efficacy and safety. SBRT is regarded as the best choice for inoperable patients, and could also be offered as an alternative to surgery to selected operable patients. More recently, its use for lung metastases progressively increased, and SBRT is now regarded as a low toxic and highly effective local therapy for lung oligometastases from different primary tumors, especially colorectal cancer...
November 30, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27912833/treatment-of-locally-advanced-non-small-cell-lung-cancer
#2
REVIEW
Kit Tam, Megan Daly, Karen Kelly
Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity...
February 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27908619/correlation-of-dna-repair-gene-polymorphisms-with-clinical-outcome-in-patients-with-locally-advanced-non-small-cell-lung-cancer-receiving-induction-chemotherapy-followed-by-surgery
#3
Mariacarmela Santarpia, Jose Luis Ramirez, Itziar de Aguirre, Pilar Garrido, Maria Pérez Cano, Cristina Queralt, Jose Luis Gonzalez-Larriba, Amelia Insa, Mariano Provencio, Dolores Isla, Carlos Camps, Remei Blanco, Teresa Moran, Rafael Rosell
OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival...
November 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27903462/radiomic-based-pathological-response-prediction-from-primary-tumors-and-lymph-nodes-in-nsclc
#4
Thibaud P Coroller, Vishesh Agrawal, Elizabeth Huynh, Vivek Narayan, Stephanie W Lee, Raymond H Mak, Hugo J W L Aerts
INTRODUCTION: Non-invasive biomarkers that capture the total tumor burden could provide important complementary information for precision medicine to aid clinical decision-making. We investigated the value of radiomic data, extracted from pre-treatment computed tomography (CT) images of the primary tumor and lymph nodes, in predicting pathological response following neoadjuvant chemoradiation prior to surgery. METHODS: Eighty-five patients with resectable locally-advanced (stage II-III) non-small cell lung cancer (NSCLC) (median age: 60...
November 26, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27896639/seom-clinical-guideline-for-bone-metastases-from-solid-tumours-2016
#5
C Grávalos, C Rodríguez, A Sabino, M Á Seguí, J A Virizuela, A Carmona, J Cassinello, D Isla, C Jara, M Martín
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27811857/phase-ii-study-of-chemoselection-with-docetaxel-plus-cisplatin-and-5-fluorouracil-induction-chemotherapy-and-subsequent-conversion-surgery-for-locally-advanced-unresectable-oesophageal-cancer
#6
Tomoya Yokota, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Hiroki Hara, Takashi Ura, Takashi Kojima, Keisho Chin, Shuichi Hironaka, Takayuki Kii, Yasushi Kojima, Yasunori Akutsu, Hisayuki Matsushita, Kentaro Kawakami, Keita Mori, Yushi Nagai, Chika Asami, Yuko Kitagawa
BACKGROUND: The standard treatment for locally advanced unresectable squamous cell carcinoma (SCC) of the oesophagus is chemoradiation with cisplatin and 5-fluorouracil (CF-RT). This multicentre phase II trial assessed the safety and efficacy of chemoselection with docetaxel plus cisplatin and 5-fluorouracil (DCF) induction chemotherapy (ICT) and subsequent conversion surgery (CS) for initially unresectable locally advanced SCC of the oesophagus. METHODS: Patients with clinical T4 and/or unresectable supraclavicular lymph node metastasis were eligible...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27780780/role-of-local-ablative-therapy-in-patients-with-oligometastatic-and-oligoprogressive-non-small-cell-lung-cancer
#7
REVIEW
Chul Kim, Chuong D Hoang, Aparna H Kesarwala, David S Schrump, Udayan Guha, Arun Rajan
Due to an improved understanding of lung cancer biology and improvement in systemic treatment, an "oligometastatic" state where metastatic disease is present at a limited number of anatomic sites is being increasingly recognized. An "oligoprogressive" state, a similar but distinct entity, refers to disease progression at a limited number of anatomic sites with continued response or stable disease at other sites of disease. Such an oligoprogressive state is best described in patients with non-small-cell lung cancer (NSCLC) treated with molecular targeted therapy...
October 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27774435/combining-radiation-therapy-with-immune-checkpoint-blockade-for-central-nervous-system-malignancies
#8
REVIEW
Neil M D'Souza, Penny Fang, Jennifer Logan, Jinzhong Yang, Wen Jiang, Jing Li
Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) via anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27770782/triple-negative-breast-cancer-in-north-of-morocco-clinicopathologic-and-prognostic-features
#9
Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita
BACKGROUND: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco. METHODS: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015...
October 22, 2016: BMC Women's Health
https://www.readbyqxmd.com/read/27732994/stage-iii-non-small-cell-lung-cancer
#10
Valerie W Rusch
More than 20% of non-small cell lung cancers (NSCLCs) are classified as stage III disease at diagnosis because they are locoregionally advanced tumors. Local therapy alone (surgery or radiation) leads to poor overall survival in stage III NSCLC because most of the patients with NSCLC die of distant metastases. Therefore, during the past 20 years, studies have focused on developing effective chemotherapy regimens that can be combined with local therapies (surgery and/or radiation). The role of surgery has been extensively evaluated and the selection criteria for resection defined...
October 2016: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27720827/timing-of-surgery-after-neoadjuvant-chemoradiation-in-locally-advanced-non-small-cell-lung-cancer
#11
Sarah J Gao, Christopher D Corso, Elyn H Wang, Justin D Blasberg, Frank C Detterbeck, Daniel J Boffa, Roy H Decker, Anthony W Kim
INTRODUCTION: A subset of patients with potentially resectable clinical stage IIIA NSCLC are managed with trimodality therapy. However, little data exist to guide the timing of surgery after neoadjuvant therapy. This study examined whether the time interval between neoadjuvant chemoradiation (NCRT) and surgical resection affects overall survival. METHODS: Patients with clinical stage IIIA disease (T1-3 N2) NSCLC who underwent NCRT were identified in the National Cancer Data Base (NCDB) between 2004 and 2012 and categorized on the basis of the interval between chemoradiation and surgery (0 to ≤3, >3 to ≤6, >6 to ≤9, and >9 to ≤12 weeks)...
October 5, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27702837/role-of-multimodality-therapy-in-ciiia-n2-non-small-cell-lung-cancer-perspective
#12
Hidehito Horinouchi
A number of promising new approaches for both local and systemic control of locally advanced non-small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non-small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease...
October 4, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27675778/comparative-effectiveness-of-standard-versus-high-dose-neoadjuvant-chemoradiation-followed-by-surgery-for-locally-advanced-non-small-cell-lung-cancer
#13
J Paly, T Shaikh, W J Scott, D Flieder, H Borghaei, M A Hallman, J E Meyer
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674731/patterns-of-recurrence-in-patients-with-locally-advanced-non-small-cell-lung-cancer-lansclc-treated-with-concurrent-chemoradiation-crt-followed-by-surgery
#14
N Bhooshan, M Vyfhuis, J Feliciano, S M Bentzen, E M Nichols, M J Edelman, W Burrows, M Suntharalingam, S Carr, J Friedberg, S N Badiyan, S J Feigenberg, P Mohindra
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27630311/feasibility-of-concomitant-chemoradiotherapy-in-daily-practice-for-patients-with-nsclc-stage-iii
#15
Femke S VAN DER Meer, Franz M N H Schramel, Marco VAN Vulpen, Sherif Y El Sharouni
BACKGROUND: In patients with non-small cell lung cancer (NSCLC), approximately 25% have locally advanced disease. For patients with irresectable (N2-3 or T4) or inoperable disease, treatment consists of chemoradiotherapy. Concomitant chemoradiotherapy improves survival compared to sequential chemoradiotherapy in these patients. PATIENTS AND METHODS: Treatment plans and completion of treatment was evaluated for all patients treated at the St. Antonius Hospital from 2008-2011 for NSCLC stage IIIA/B not eligible for surgery...
September 2016: Anticancer Research
https://www.readbyqxmd.com/read/27621889/vats-right-upper-lobe-bronchial-sleeve-resection
#16
Qianli Ma, Deruo Liu
BACKGROUND: The aim of this study is to discuss video-assisted thoracic surgery (VATS) sleeve bronchial lobectomy when handling the locally advanced central lung cancer (involving the trachea and/or main bronchus). METHODS: A 2.5 cm × 1.0 cm mass was found in the right upper lobe. Bronchoscopy demonstrated the tumor obstructing the right upper lobe bronchus and involved the right main bronchus and bronchus intermedius. Interrupted sutures were chosen for bronchial anastomosis...
August 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27608595/clinical-practice-guidelines-for-prophylaxis-of-venous-thomboembolism-in-cancer-patients
#17
Corinne Frere, Dominique Farge
Symptomatic venous thromboembolism (VTE) occurs 4-7 times more frequently in cancer patients as compared to non-cancer patients. A significant number of risk factors, which can be subcategorised as patient-, cancer- or treatment-related, have been shown to influence the risk of VTE during malignancy and further incorporated in risk-assessment models. Safe and efficient thromboprophylaxis regimens allow substantial decreased in VTE rates, since VTE is most often a largely preventable disease, but thromboprophylaxis remains underused in cancer compared to non-cancer patients...
September 27, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27597290/is-vats-lobectomy-standard-of-care-for-operable-non-small-cell-lung-cancer
#18
REVIEW
Fernando Vannucci, Diego Gonzalez-Rivas
Video-Assisted Thoracic Surgery (VATS) for treatment of lung cancer is being increasingly applied worldwide in the last few years. Since its introduction, many publications have been providing strong evidences that this minimally invasive approach is feasible, safe and oncologically efficient; offering to patients several advantages over traditional open thoracotomy, particularly for early-stage disease (I and II). The application of VATS for locally advanced disease treatment has also been largely described, but probably requires a further level of experience, which is more likely to be found in reference centers, with skilled experts...
October 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27596221/proton-therapy-posterior-beam-approach-with-pencil-beam-scanning-for-esophageal-cancer-clinical-outcome-dosimetry-and-feasibility
#19
Yue-Can Zeng, Shilpa Vyas, Quang Dang, Lindsay Schultz, Stephen R Bowen, Veena Shankaran, Farhood Farjah, Brant K Oelschlager, Smith Apisarnthanarax, Jing Zeng
PURPOSE: The aim of this study is to present the dosimetry, feasibility, and preliminary clinical results of a novel pencil beam scanning (PBS) posterior beam technique of proton treatment for esophageal cancer in the setting of trimodality therapy. METHODS: From February 2014 to June 2015, 13 patients with locally advanced esophageal cancer (T3-4N0-2M0; 11 adenocarcinoma, 2 squamous cell carcinoma) were treated with trimodality therapy (neoadjuvant chemoradiation followed by esophagectomy)...
September 5, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27575277/pulmonary-resection-for-a-residual-tumor-after-definitive-radiation-in-locally-advanced-non-small-cell-lung-cancer
#20
Tetsuzo Tagawa, Kensaku Ito, Kengo Fukuzawa, Akira Motohiro
Objective and Methods To clarify the benefits of surgery for a persistent tumor following definitive radiation in locally advanced non-small cell lung cancer, five patients were retrospectively reviewed. Results All patients received definitive radiation, and three received concurrent chemotherapy followed by anatomical lung resection for a residual local tumor. The median time from the radiation to surgery was 8.2 weeks. There were no postoperative mortalities. Four patients developed distant metastasis with a mean recurrence-free interval of 7...
August 30, 2016: Thoracic and Cardiovascular Surgeon
keyword
keyword
28518
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"